1
|
Li J, Wei S, Marabada D, Wang Z, Huang Q. Research Progress of Natural Matrine Compounds and Synthetic Matrine Derivatives. Molecules 2023; 28:5780. [PMID: 37570750 PMCID: PMC10421345 DOI: 10.3390/molecules28155780] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 07/15/2023] [Accepted: 07/21/2023] [Indexed: 08/13/2023] Open
Abstract
Matrine is a quinoline alkaloid extracted and separated from the dried root, fruit, and other parts of the plant Sophora flavescens using an organic solvent. Matrine exhibits a variety of biological activities and is widely used in pharmacy, agronomy, and other fields. Due to its low bioavailability, poor chemical stability, and toxicity to the central nervous system, a large number of researchers have searched for matrine derivatives with higher biological activity and safety by modifying its structure. In this review article, the research progress of matrine derivatives obtained using two methods (extraction from Sophora flavescens and structural modifications) from 2018 to 2022 in terms of pharmacological activity, mechanism of action, and structure-activity relationship are presented. The modification of matrine over the past five years has been mainly on the D-ring. Many new matrine alkaloids have been extracted from natural products, some of which have good pharmacological activity, which broadens the strategy for matrine structural modification in the future.
Collapse
Affiliation(s)
- Jinlei Li
- School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China; (J.L.); (D.M.)
| | - Shijie Wei
- Pharmacy Department, General Hospital of Ningxia Medical University, Yinchuan 750004, China;
| | - Davies Marabada
- School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China; (J.L.); (D.M.)
| | - Zhizhong Wang
- School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China; (J.L.); (D.M.)
| | - Qing Huang
- School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China; (J.L.); (D.M.)
| |
Collapse
|
2
|
Sun XY, Jia LY, Rong Z, Zhou X, Cao LQ, Li AH, Guo M, Jin J, Wang YD, Huang L, Li YH, He ZJ, Li L, Ma RK, Lv YF, Shao KK, Zhang J, Cao HL. Research Advances on Matrine. Front Chem 2022; 10:867318. [PMID: 35433636 PMCID: PMC9010661 DOI: 10.3389/fchem.2022.867318] [Citation(s) in RCA: 27] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Accepted: 02/22/2022] [Indexed: 11/13/2022] Open
Abstract
Matrine is an alkaloid extracted from traditional Chinese herbs including Sophora flavescentis, Sophora alopecuroides, Sophora root, etc. It has the dual advantages of traditional Chinese herbs and chemotherapy drugs. It exhibits distinct benefits in preventing and improving chronic diseases such as cardiovascular disease and tumors. The review introduced recent research progresses on extraction, synthesis and derivatization of Matrine. The summary focused on the latest research advances of Matrine on anti-atherosclerosis, anti-hypertension, anti-ischemia reperfusion injury, anti-arrhythmia, anti-diabetic cardiovascular complications, anti-tumor, anti-inflammatory, anti-bacterium, anti-virus, which would provide new core structures and new insights for new drug development in related fields.
Collapse
Affiliation(s)
- Xiao-Ying Sun
- College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, China
| | - Li-Yi Jia
- College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, China
| | - Zheng Rong
- College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, China
| | - Xin Zhou
- Xi’an Key Laboratory of Basic and Translation of Cardiovascular Metabolic Disease, Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi’an Medical University, Xi’an, China
| | - Lu-Qi Cao
- Xi’an Key Laboratory of Basic and Translation of Cardiovascular Metabolic Disease, Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi’an Medical University, Xi’an, China
| | - Ai-Hong Li
- Shaanxi Key Laboratory of Chinese Herb and Natural Drug Development, Medicine Research Institute, Shaanxi Pharmaceutical Holding Group Co., LTD, Xi’an, China
| | - Meng Guo
- College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, China
| | - Jie Jin
- College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, China
| | - Yin-Di Wang
- College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, China
| | - Ling Huang
- College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, China
| | - Yi-Heng Li
- College of Life Sciences, Northwest University, Xi’an, China
| | - Zhong-Jing He
- College of Life Sciences, Northwest University, Xi’an, China
| | - Long Li
- Xi’an Key Laboratory of Basic and Translation of Cardiovascular Metabolic Disease, Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi’an Medical University, Xi’an, China
| | - Rui-Kang Ma
- Xi’an Key Laboratory of Basic and Translation of Cardiovascular Metabolic Disease, Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi’an Medical University, Xi’an, China
| | - Yi-Fan Lv
- Xi’an Key Laboratory of Basic and Translation of Cardiovascular Metabolic Disease, Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi’an Medical University, Xi’an, China
| | - Ke-Ke Shao
- Xi’an Key Laboratory of Basic and Translation of Cardiovascular Metabolic Disease, Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi’an Medical University, Xi’an, China
| | - Juan Zhang
- College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, China
- *Correspondence: Juan Zhang, ; Hui-Ling Cao,
| | - Hui-Ling Cao
- College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, China
- Xi’an Key Laboratory of Basic and Translation of Cardiovascular Metabolic Disease, Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi’an Medical University, Xi’an, China
- Shaanxi Key Laboratory of Chinese Herb and Natural Drug Development, Medicine Research Institute, Shaanxi Pharmaceutical Holding Group Co., LTD, Xi’an, China
- College of Life Sciences, Northwest University, Xi’an, China
- *Correspondence: Juan Zhang, ; Hui-Ling Cao,
| |
Collapse
|
3
|
Wei Y, Wang H, Xi C, Li N, Li D, Yao C, Sun G, Ge H, Hu K, Zhang Q. Antiviral Effects of Novel 2-Benzoxyl-Phenylpyridine Derivatives. Molecules 2020; 25:E1409. [PMID: 32204528 PMCID: PMC7144376 DOI: 10.3390/molecules25061409] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Accepted: 03/06/2020] [Indexed: 01/19/2023] Open
Abstract
Coxsackievirus B3 (CVB3) is the most common cause of acute and chronic viral myocarditis, primarily in children, while human adenovirus infections represent a significant cause of morbidity and mortality worldwide, in people of all ages. A series of novel 2-benzoxyl-phenylpyridine derivatives were evaluated for their potential antiviral activities against CVB3 and adenovirus type 7 (ADV7). Preliminary assays indicated that some of these compounds exhibited excellent antiviral effects on both CVB3 and ADV7 viruses; they could effectively inhibit virus-induced cytopathic effects, reduce viral progeny yields, and had similar or superior antiviral activities compared with the control drug, ribavirin. Further, these compounds targeted the early stages of CVB3 replication in cells, including viral RNA replication and protein synthesis, rather than inactivating the virus directly, inhibiting virus adsorption/entry, or affecting viral release from cells. Our data demonstrate that the tested 2-benzoxyl-phenylpyridine derivatives are effective inhibitors of CVB3 and ADV7, raising the possibility that these compounds might be feasible candidates for anti-viral agents.
Collapse
Affiliation(s)
- Yanhong Wei
- National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Sino-German Biomedical Center, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China; (Y.W.); (H.W.); (C.X.); (N.L.); (C.Y.); (G.S.); (H.G.)
| | - Haijie Wang
- National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Sino-German Biomedical Center, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China; (Y.W.); (H.W.); (C.X.); (N.L.); (C.Y.); (G.S.); (H.G.)
| | - Caili Xi
- National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Sino-German Biomedical Center, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China; (Y.W.); (H.W.); (C.X.); (N.L.); (C.Y.); (G.S.); (H.G.)
| | - Ni Li
- National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Sino-German Biomedical Center, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China; (Y.W.); (H.W.); (C.X.); (N.L.); (C.Y.); (G.S.); (H.G.)
| | - Dong Li
- School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China;
| | - Chenguang Yao
- National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Sino-German Biomedical Center, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China; (Y.W.); (H.W.); (C.X.); (N.L.); (C.Y.); (G.S.); (H.G.)
| | - Ge Sun
- National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Sino-German Biomedical Center, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China; (Y.W.); (H.W.); (C.X.); (N.L.); (C.Y.); (G.S.); (H.G.)
| | - Hongmei Ge
- National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Sino-German Biomedical Center, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China; (Y.W.); (H.W.); (C.X.); (N.L.); (C.Y.); (G.S.); (H.G.)
| | - Kanghong Hu
- National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Sino-German Biomedical Center, School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China; (Y.W.); (H.W.); (C.X.); (N.L.); (C.Y.); (G.S.); (H.G.)
| | - Qian Zhang
- School of Materials and Chemical Engineering, Hubei University of Technology, Wuhan 430068, China;
| |
Collapse
|
4
|
Bonam SR, Ruff M, Muller S. HSPA8/HSC70 in Immune Disorders: A Molecular Rheostat that Adjusts Chaperone-Mediated Autophagy Substrates. Cells 2019; 8:E849. [PMID: 31394830 PMCID: PMC6721745 DOI: 10.3390/cells8080849] [Citation(s) in RCA: 62] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2019] [Revised: 08/02/2019] [Accepted: 08/05/2019] [Indexed: 12/24/2022] Open
Abstract
HSPA8/HSC70 is a molecular chaperone involved in a wide variety of cellular processes. It plays a crucial role in protein quality control, ensuring the correct folding and re-folding of selected proteins, and controlling the elimination of abnormally-folded conformers and of proteins daily produced in excess in our cells. HSPA8 is a crucial molecular regulator of chaperone-mediated autophagy, as a detector of substrates that will be processed by this specialized autophagy pathway. In this review, we shortly summarize its structure and overall functions, dissect its implication in immune disorders, and list the known pharmacological tools that modulate its functions. We also exemplify the interest of targeting HSPA8 to regulate pathological immune dysfunctions.
Collapse
Affiliation(s)
- Srinivasa Reddy Bonam
- Neuroimmunology & peptide therapy, Biotechnology and cell signaling, CNRS-University of Strasbourg, Illkirch 67412, France/Laboratory of excellence Medalis, 67000 Strasbourg, France
| | - Marc Ruff
- Biologie Structurale Intégrative, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, 67404 Strasbourg, France
| | - Sylviane Muller
- Neuroimmunology & peptide therapy, Biotechnology and cell signaling, CNRS-University of Strasbourg, Illkirch 67412, France/Laboratory of excellence Medalis, 67000 Strasbourg, France.
- University of Strasbourg Institute for Advanced Study (USIAS), 67000 Strasbourg, France.
- Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg University, 67000 Strasbourg, France.
| |
Collapse
|